3P BIOTECHNOLOGIES, INC.

Prospect, KY · Biotech · Private

Exosome-based delivery system for CRISPR/Cas9 genome editing using engineered milk exosomes with targeted ligand functionalization

3pbiotechnologies.com →
Grants
$4.5M
7 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
1 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Exosomal Drug Delivery$1,719,680
Federal grantDepartment of Health and Human Services · Phase II · Exosomal Drug Delivery$1,000,000
Federal grantDepartment of Health and Human Services · Phase I · Engineered Exosomes for Targeted Delivery of the CRISPR/Cas9 Genome-editor$264,507
Federal grantDepartment of Health and Human Services · Phase I · Targeted Exosomal Delivery of siRNA Therapeutics for Neuroinflammatory Diseases$506,451
Federal grantDepartment of Health and Human Services · Phase I · Trans Spinal Delivery of a Targeted Nanoformulation of Curcuminoids to Treat AD$499,964
Federal grantDepartment of Health and Human Services · Phase I · Trans Spinal Delivery of a Targeted Nanoformulation of Curcuminoids to Treat AD$6,500
Federal grantDepartment of Health and Human Services · Phase I · Trans Spinal Delivery of Targeted Exosomal Formulation of Curcuminoids to Treat AD$506,434
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2334NEMAMETRIX, INC—$9.4M
2335TERAIMMUNE, INC.—$3.0M
2336Decibel Therapeutics—$63M
23373P BIOTECHNOLOGIES, INC.——
2338Mythic Therapeutics—$53M
2339DEEPSEQAI LLC——
2340Tallac Therapeutics, Inc.—$21M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 2

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.